CRO Syneos Health and Medable have extended their partnership that was formed in the spring of 2021 to boost decentralized clinical trials and improve patient diversity.
In the past 18 months since the two companies teamed up, they have collaborated on more than 15 clinical trials that span multiple therapeutic areas, Syneos said in a Dec. 13 press release.
Financial terms of the deal weren’t disclosed.
“With continued increased demand for DCTs across the industry, our ongoing collaboration with Medable reinforces Syneos Health’s commitment to providing sponsors with solutions that drive efficiency, reduce costs and better engage patients,” Maria Fotiu, Syneos’ president, sites and patients, decentralized solutions, said in the release.
Medable first joined with Syneos the same week in April 2021 that it raised $78 million in a third round of funding. That round came less than six months after it hauled in $91 million in the wake of the COVID-19 pandemic’s disruption of physical trial sites that rocketed the acceptance of DCTs.
The initial deal gave Syneos access to Medable’s digital platform that helped the CRO grow its siteless study platform. The technology allowed the introduction of elements such as telemedicine and connected devices to help trial patients participate from home.